Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

Name: Αlpha¹ Rigor Record — Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
Item: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin
Rating: 59
Author: Αlpha¹

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR, Australasian Leukaemia and Lymphoma Group.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2★ (Weak), 0 critical, 8 high issues for “Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingKey resources not met−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingStatistical analysis partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
No data or code availability links were detected to verify.

Problems surfaced7 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps4

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Key resources not identifiedAssessed
Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Ethics/consent reporting incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The CAST trial is a well-designed randomized phase 3 study with a clear scientific premise, adequate design, and transparent reporting in most dimensions. However, it has significant gaps in key resources (missing drug manufacturers and statistical software), data availability (no data access statement), and a minor ethical reporting gap (no regulatory framework cited). The statistical analysis is adequate but reports the primary p-value only as a threshold. Two internal contradictions (age range, survival estimate) and an overstated conclusion about changing clinical practice warrant attention.

Both reviewers were independent runs of the same model and agreed on most dimensions, diverging only on key resources (fail vs. warn) and in sub-criterion ratings for randomization method and demographics. The statistics verification component checked only a subset of reported tests; no arithmetic errors were found, but the absence of a full check means we cannot confirm the correctness of all analyses. The citation check found no retracted or non-existent references.

10 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions4 pass · 2 warn · 2 fail

The background cites the two key randomized trials (BMT CTN 1703 and HOVON-96) and explains their limitations — HOVON-96 'predominantly involved matched unrelated donors and exclusively used non-myeloablative conditioning' and BMT CTN 1703 did not include myeloablative conditioning — which directly motivates the trial. The rationale linking this gap to the study objective is explicit, and the trial is positioned to address the myeloablative (previously 'unknown') context.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is well established: prior randomized evidence (BMT CTN 1703, HOVON-96, ATG trials) is cited with its strengths and limitations, and the specific knowledge gap (PTCy in MRD PBSCT with myeloablative conditioning) is clearly articulated.

Evidence

paraphrase[Background, paragraph 2]

“However, this study predominantly involved matched unrelated donors and exclusively used non-myeloablative conditioning.”

direct quote[Background, final paragraph]

“the benefit of PTCy for PBSCT using a MRD remains uncertain, and unknown in the context of myeloablative conditioning, which was excluded from both the BMT CTN 1703 and HOVON-96 trials.”